

Mthfr c677t, Homocysteine and Risk of Splanchnic Vein Thrombosis: A Pooled Analysis of Published Epidemiological Studies

Li SL^{*1}, Yue XY², Wang H³, Zhang L¹ and Lu ZJ⁴

¹Statistics Office of Information Center, Department of Radiology, The Affiliated Hospital of Xu Zhou Medical College, China

²Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin

³Trauma Department of Xuzhou Central Hospital, China

⁴School of Public Health Xuzhou Medical College, China

***Corresponding author:** Li SL, Statistics Office of Information Center, The Affiliated Hospital of Xu Zhou Medical College, China, Fax: +86-516-83262121, Tel: +86-516-85802343, E-mail: lishengli401@163.com

Citation: Li SL, Yue XY, Wang H, Zhang L, Lu ZJ (2015) Mthfr c677t, Homocysteine and Risk of Splanchnic Vein Thrombosis: A Pooled Analysis of Published Epidemiological Studies. *J Genet Mutat Disor* 1(1): 101

Abstract

Objective: This meta-analysis aimed to comprehensively assess the literature examining a possible link between the methylenetetrahydrofolate reductase (MTHFR) C677T gene mutation and homocysteine and the risk of splanchnic vein thrombosis (SVT).

Methods: Electronic databases were searched up to November 2014 for published case-control studies investigating genetic polymorphisms or the homocysteine level associated with SVT patients, including Budd-Chiari syndrome (BCS), portal vein thrombosis (PVT) and mesenteric vein thrombosis (MVT). Data on year of publication, study design, country of origin, number of patients/control subjects, were abstracted. Pooled odds ratios (OR) or weighted mean difference with 95% confidence interval were calculated using a random-effects model.

Results: We initially identified and screened 72 relevant studies for retrieval, and included 24 in our final analysis. Statistically significant associations with SVT were found for MTHFR C677T (OR=2.09; 95% CI, 1.66 to 2.64; P<0.01). In subgroup analysis, similar results were also observed in PVT (OR=1.73, 95% CI=1.21 to 2.48, P<0.01) and MVT (OR= 3.14; 95% CI, 1.97 to 5.01, P<0.01). However, the meta-analysis of the OR found in our current study for MTHFR/C677T in BCS generated a pooled observed OR of 1.36 (OR=1.36; 95% CI, 0.61 to 3.02, P>0.05). The plasma homocysteine level was significantly higher in SVT patients than in healthy controls (SMD = 0.50, 95% CI = 0.12–0.87, P = 0.010)

Conclusion: Our results suggest that MTHFR C677T gene mutation and the homocysteine level may be associated with SVT.

Keywords: Splanchnic vein thrombosis; Budd-Chiari syndrome; Portal vein thrombosis; Mesenteric vein thrombosis; Methylenetetrahydrofolate reductase; Homocysteine; Meta-analysis

Introduction

Splanchnic vein thrombosis (SVT), that is hepatic, portal, mesenteric or splenic vein thrombosis, is a rare and life-threatening vascular disorder associated with highly variable clinical expression, including Budd-Chiari syndrome (BCS), portal vein thrombosis (PVT) and mesenteric vein thrombosis (MVT) [1]. BCS results from hepatic venous outflow obstruction at any level, from hepatic venules to the right atrium [2]. PVT refers to thrombosis within the extrahepatic portal vein, mesenteric vein and splenic vein. BCS and PVT are two major vascular disorders of the liver [3]. Acute mesenteric venous thrombosis (MVT) is an uncommon disorder with non-specific signs and symptoms. The diagnosis of which requires a high index of suspicion [4]. SVT is an under diagnosed disease, with heterogeneous clinical presentations and a non-negligible rate of incidental findings. Several risk factors have been identified, including inherited or acquired coagulation disorders (that is, factor V Leiden, factor II, and antiphospholipid syndrome) [5,6].

Furthermore, methylenetetrahydrofolate reductase (MTHFR) located in 1p36.3, which plays an important role in processing amino acids and building blocks of proteins as a crucial enzyme for the metabolism of folate. MTHFR converts 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. Then, the methionine was used by body to make proteins and other important compounds [7]. The missense mutation, C677T has become the most commonly studied one, which has been considered to influence the enzyme activity of MTHFR [8]. A string of epidemiological studies have evaluated the association between the MTHFR C677T mutation and SVT risk [9-31]. In patients with homozygous MTHFR C677T mutation, MTHFR activity is reduced,

thereby resulting in an elevation of serum homocysteine concentrations of about 20% that is a well-recognized risk factor of venous and arterial thrombosis [32-34]. The role that the C677T mutation in MTHFR plays in SVT remains unclear due to this unusual thrombotic location. However, these studies have yielded conflicting results, partially because of the possible small effect of the polymorphism on SVT risk and the relatively small sample size in each of published studies.

Therefore, the aim of this study is to derive a more precise estimation of the association between the MTHFR C677T point mutation and SVT by conducting a meta-analysis of epidemiological studies on this topic and to evaluate the significance of homocysteine level in SVT.

Methods

We designed and reported the meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement [26].

Publication search

The study search was performed independently by two authors (Li and Zhang). The most recent on-line versions of the following research databases were searched up to November 2013 without language restrictions: Wanfang, Chinese Biomedicine databases, Pub Med, Embase and Web of Knowledge. The following search terms were used to identify studies: methylenetetrahydrofolate reductase or MTHFR or MTHFR C677T, homocysteine, hyperhomocysteinemia, splanchnic vein thrombosis, portal vein thrombosis, mesenteric vein thrombosis, Budd-Chiari syndrome, gene or polymorphism or variation, mutation. All of the studies searched were retrieved, and the references cited in the studies were also reviewed to identify additional published work. Animal studies, simply commentaries, case reports and unpublished reports were excluded. Review articles were also screened to identify additional eligible studies.

Selection criteria

We included in the systematic review full-length research studies that satisfied the following criteria: 1) prospective or case-control studies; 2) studies on the effect of the MTHFR polymorphism on SVT; 3) genotype frequencies available in both cases and controls; and 4) they provided sufficient published data for estimating an odds ratio (OR) with a 95% confidence interval (95%CI). Accordingly, articles were excluded using the following criteria: 1) reviews, abstracts and repeat studies; 2) studies with incomplete data or zero observations in cases or controls were excluded. For the studies with the same or overlapping data by the same authors, the most suitable study with the greatest number of subjects or the most recently published study was selected.

Data extraction

Two authors (Yue and Wang) independently extracted the following data from included studies: first author's name, publication date, numbers of cases and controls, country, ethnicity, study design, source of controls, and number of C677T genotypes for both cases and controls. Extracted data were compared and discrepancies resolved by discussion. When necessary, another author (Lu) was consulted to resolve the dispute.

Statistical methods

The meta-analysis mainly was used to assess the strength of the association between the MTHFR C677T mutation and SVT risk based on the genotype frequencies in cases and controls. The effect of association was indicated as the odds ratio (OR) with the corresponding 95% confidence interval (CI). All statistical tests for this meta-analysis were performed by using Stata 12.0 (Stata Corp, College Station, USA). We pooled data using the DerSimonian-Laird random effects method, which recognizes and anchors studies as a sample of all potential studies, and incorporates an additional between-study component to the estimate of variability [35]. Therefore, the random-effects model was applied in our meta-analysis to generate a more conservative estimate of the proportion. Heterogeneity was quantified using the I^2 metric, which is independent of the number of studies in the meta-analysis ($I^2 < 25\%$ no heterogeneity; $I^2 = 25\text{-}50\%$ moderate heterogeneity; $I^2 > 50\%$ large or extreme heterogeneity) [36]. The bias (such as publication and location bias) was investigated by funnel plot. An asymmetric plot suggested possible publication bias. It was assessed quantitatively by a linear regression test that Egger et al defined [28]. A regression line which passes through the origin of the plot (within error limits) indicates symmetry and hence the absence of bias. Begg's test and Egger's test were used to statistically assess publication bias and a p value of < 0.05 was considered significant. Statistical significance was taken as $p < 0.05$ and all tests were two-sided.

Results

Characteristics of Including Studies

Figure 1 shows the literature search and study selection procedures. Our literature search identified 72 publications, of which 41 were excluded after review of the title and abstract. Seven publications were further excluded after review of full-text because of the following reasons: no report of the association between MTHFR C677T polymorphism and SVT (3 studies), without case-control or TDT design (1 study), data duplication (2 studies) and lack of sufficient data (1 study). Thus, 26 publications involving 1344 ca-

ses and 2856 controls in 22 case-control studies and 2 prospective studies were ultimately included [9-26,33,34,37-40]. Of these 24 studies, 9 were conducted in Asia, 11 in Europe, 2 in America, and 2 in Africa. Studies ranged in size from 12 to 262 patients. Table 1 shows the characteristics of the included studies.




Figure 1: Flow chart of the retrieved steps of our meta-analysis

Author,Year	Ethnicity	Study	N(Ca/Con)	Case/ Control	Sex (M,F)
Amitrano et al,2000	Europe/ Italy	case-control	23/471	PVT/ healthy subjects	NA
Amitrano et al,2001	Europe/ Italy	case-control	12/431	MVT/ healthy subjects	(8,4)/(244,187)
Amitrano et al,2003	Europe/ Italy	case-control	17/244	SVT/ healthy subjects and non-thrombotic	(5,12)/(NA)
Heller et al,2000	Europe/Germany	case-control	24/100	PVT/ healthy neonates and infants	NA
Li et al,2002	Asia/ China	case-control	41/80	BCS/ healthy neonates and infants	(30,11)/(51,29)
Pinto et al,2003	Americas/Brazil	case-control	14/28	PVT/ healthy, age- and sex-matched individuals	NA
Pinto et al,2004	Americas/Brazil	prospective	14/28	PVT/children without hepatopath	(7,7)/(NA)
Saxena et al,2004	Asia /India	case-control	105/68	BCS and PVT/ control group free of liver disease	(64,51)/(NA)
Erkan et al,2005	Asia/ Turkey	case-control	36/80	PVT/ healthy age- and sex-matched persons	(22,14)/(46,34)
Mangia et al,2005	Europe/ Italy	prospective	43/176	PVT/ healthy volunteers	(22,21)/(90,86)
Agaoğlu et al,2005	Asia/ Turkey	case-control	28/103	MVT/ cirrhotic patients without PVT	(16,12)/(60,43)
Pasta et al,2006	Europe/ Italy	case-control	78/78	PVT/ healthy controls	(50,28)/(55,23)
D'Amico et al,2009	Europe/ Italy	case-control	94/94	PVT/ cirrhotic patients without PVT	NA
Gabr et al,2010	Africa /Egypt	case-control	76/20	PVT/ healthy age- and sex- matched volunteers	(47,29)/(10,10)
He et al,2010	Asia/ China	case-control	63/128	MVT/ sex- and age-matched healthy individuals	(49,14)/(95,33)
Vaya et al,2011	Europe/Spain	case-control	48/84	PVT,BCS and MVT/ healthy individuals	(26,22)/(NA)
Hoekstra et al,2010	Europe/7countries	case-control	262/116	PVT and BCS/ Healthy controls	(119,143)/(NA)
Amitrano et al,2004	Europe/ Italy	case-control	79/79	LC with PVT/ LC without PVT	(47,32)/(47,32)
Chamouard et al,2001	Europe /France	case-control	22/60	PVT without LC/ DVT	NA

Author,Year	Ethnicity	Study	N(Ca/Con)	Case/ Control	Sex (M,F)
Colak et al.,2006	Asia/ Turkey	case-control	32/33	BCS/ Healthy controls	(16,16)/(15,18)
Hu et al,2008	Asia/ China	case-control	63/75	MVT/ healthy individuals	(49,14)/(56,19)
Maras et al,2010	Asia /India	case-control	70/200	LC with PVT/ LC without PVT	NA
Salama et al,2007	Africa /Egypti	case-control	40/20	PVT without LC/ Healthy controls	(27,13)/(14,6)
Tian et al,2012	Asia/ China	case-control	60/60	BCS/Healthy controls	(33,27)/(28,32)

NA, not available;

Table 1: Baseline characteristics of studies included in the meta-analysis

The Association between MTHFRC677T Polymorphism and SVT

The homozygous methylene tetrahydrofolate reductase (MTHFR)/C677T polymorphism (Figure 2) was investigated in a total of 22 studies in 3773 subjects (1265 cases and 2508 controls), providing a pooled OR of 2.09 (95% CI, 1.66 to 2.64; $P < 0.01$). There was little heterogeneity among 22 studies with this outcome ($P = 0.203$, $I^2 = 19.6\%$). Visual inspection of Begg’s funnel plots did not show any substantial asymmetry ($z = 0.31$, $P = 0.756$). Egger’s regression test also indicated little evidence of publication bias ($t = -0.42$, $P = 0.677$) (Figure 3).




Figure 2: Forest plot assessing the potential association between MTHFRC677T and risk of SVT in all included studies




Figure 3: Funnel plot of MTHFR C677T point mutation and risk of SVT

MTHFR C677T and PVT

Sixteen studies evaluated the risk between MTHFR C677T and PVT. In subgroup analysis, MTHFR C677T was significantly higher in PVT versus controls (OR=1.73, 95% CI=1.21 to 2.48, $P<0.01$). There was moderate heterogeneity among 16 studies with this outcome ($P=0.023$, $I^2=45.9\%$). (Figure 4) Visual inspection of Begg's funnel plots did not show any substantial asymmetry ($z=0.04$, $P=0.967$). Egger's regression test also indicated little evidence of publication bias ($t=1.99$, $P=0.065$).




Figure 4: Forest plot assessing the potential association between MTHFR C677T and risk of PVT, BCS and MVT in all included studies

MTHFR C677T and BCS

Only six studies evaluated the risk between MTHFR C677T and BCS. Data were obtained from 6 studies involving 318 cases with BCS and 508 controls. A meta-analysis of the OR found in our current study for MTHFR C677T in BCS generated a pooled observed OR of 1.36 (95% CI=0.61 to 3.02, $P>0.05$). The CIs for the expected OR fall entirely within the CI for the observed OR, suggesting a causal relation between MTHFR C677T and BCS. There was large heterogeneity among six studies with this outcome ($P=0.003$, $I^2=71.9\%$) (Figure 4).

MTHFR C677T and MVT

The homozygous MTHFR C677T polymorphism was investigated in five studies. These totalled 998 subjects (177 mesenteric vein thrombosis cases; 821 controls) providing a pooled OR of 3.14 (95% CI=1.97 to 5.01, $P<0.01$) with a recessive random-effects model. There was no evidence of inter-study heterogeneity ($P=0.343$, $I^2=11.0\%$) (Figure 4).

The Association between the plasma homocysteine and SVT

Data were obtained from 6 retrospective studies (419 cases and 579 controls). The heterogeneity among studies was significant ($P<0.01$, $I^2=57.4\%$). Using a random-effects model, the plasma homocysteine level was significantly higher in SVT patients than in healthy controls (SMD=0.50, 95% CI=0.12–0.87, $P=0.010$) (Figure 5).




Figure 5: Forest plot assessing the potential association between homocysteine and risk of SVT in all included studies

Discussion

The overall meta-analysis results of prospective and retrospective epidemiological studies indicated that the MTHFR C677T mutation seems to be a risk factor for SVT with little heterogeneity. This study also showed highly significant associations between homocysteine level in SVT risk. Likewise, in subgroup analysis, positive results were detected between MTHFR C677T mutation and PVT with lower heterogeneity. Similarly positive results were also found in MVT with little heterogeneity. However, the subgroup meta-analysis only comprising 4 studies showed non significant association between MTHFR C677T mutation and BCS with large heterogeneity. To the best of our knowledge, this current meta-analysis firstly integrated the prospective and case-control studies to reflect the precision effect of MTHFR C677T polymorphism and homocysteine level in SVT risk.

It is well known that hyperhomocysteinemia to cause venous and arterial thromboembolism. Two early meta-analysis of the results demonstrated a significantly increased risk of venous thromboembolism in patients with elevated plasma homocysteine levels [41,42]. Several investigations have shown that the thermolabile mutant of MTHFR causes moderate hyperhomocysteinemia [43]. Because the C677T point mutation in the encoding region of the MTHFR gene closely related to hyperhomocysteinemia, converting the codon for alanine to valine [44]. Meta-analysis of studies also suggested that hyperhomocysteinemia was a risk factor for venous thrombosis [45,45]. Our overall meta-analysis result was similar with these results.

However, caution is required when interpreting these results given the small sample size, which is inherent to the rarity of SVT. As a consequence, data obtained from this meta-analysis have to be interpreted with caution, especially for BCS and MVT. Recent studies have shown that primary BCS should be regarded as a multifactorial disease, and that co-occurrence of several prothrombotic disorders leads to thrombosis at this uncommon location. BCS is less common in western countries but primary membranous obstruction of the inferior vena cava (IVC) is the most common cause of BCS in South Africa and Asia [29,47]. MTHFR gene mutation was the first most common etiology of BCS in the current study, evident in 71.1% of patients, of whom 61.5% were heterozygotes and 9.6% homozygotes, but there was no control group [48]. In our meta-analysis, BCS was only from Asia and Europe which may affect the reliability of the results [11,13,19,26]. And as far as stratified analysis of sample size was concerned, positive results were detected in the large-sample-size subgroup but not in the small-sample-size, implying the null association was probably caused by limited sample size. These findings, in light of our meta-analysis results, highlight the need for rigorous, large-scale prospective studies that confirmed whether MTHFR C677T mutation and homocysteine play a role in the pathogenesis of the BCS.

Despite we have made great efforts to collect all possible data for investigating between MTHFR C677T polymorphism and SVT, but several potential limitations inherent in our meta-analysis should be acknowledged. First, both prospective and retrospective studies are influenced by confounding due to age, sex, smoking and body mass index. Second, most studies included in this meta-analysis involved less than a few hundred cases, and so the confidence intervals around the odds ratios were wide. Third, publication bias is a potential problem for interpretation the results in meta-analysis. When we collected full-text articles in our research, excluded abstract and unpublished articles, and positive results may be easily accepted by journals, potential publication bias may occur. Fourth, all included studies were conducted over different time periods (2000-2011); therefore, it is possible that diagnosis and treatment modalities and referral patterns may have changed over time. Fifth, a considerable heterogeneity amongst the included studies was noticed. Therefore, the random-effects model was applied in our meta-analysis to generate a more conservative estimate of the proportion.

Despite of some limitations, our meta-analysis demonstrated that MTHFR C677T polymorphism and homocysteine may be the risk factors for PVT and MVT. Subgroup meta-analysis results failed to provide compelling evidence of an association between the MTHFR C677T gene mutation and risk of BCS. Therefore, more studies with large sample sizes are required to confirm the current findings and explore the interaction between genetic polymorphism, homocysteine and SVT risk.

Acknowledgement

The authors are solely responsible for the design and conduct of this study, all study analyses and drafting and editing of the manuscript and its final contents. All authors critically reviewed the manuscript for important intellectual content and approved the final manuscript. The authors have no conflicts of interest.

References

- Regina S, Herault O, Alteroche D, Binet C, Gruel Y (2007) JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. *J Thromb Haemost* 5: 859–61.
- Murad DS, Plessier A, Guerra HM, Fabris F, Eapen CE, et al. (2009) Etiology, management, and outcome of the Budd-Chiari syndrome. *Ann Intern Med* 2009 151: 167-75.
- De Stefano V, Martinelli I (2010) Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. *Intern Emerg Med* 5: 487-94.
- Harnik IG, Brandt LJ (2010) Mesenteric venous thrombosis. *Vasc Med* 15: 407-18.
- Amitrano L, Brancaccio V, Guardascione M, Margaglione M, Iannaccone L, et al. (2000) Inherited Coagulation Disorders in Cirrhotic Patients With Portal Vein Thrombosis. *Hem Pathol* ; 31: 345-8.
- Riva N, Donadini MP, Dentali F, Squizzato A, Ageno W (2012) Splanchnic vein thrombosis. *Phlebologie* 41: 135-9.
- Goyette P, Frosst P, Rosenblatt DS, Rozen R, (1995) Seven Novel Mutations in the Methylenetetrahydrofolate Reductase Gene and Genotype/Phenotype Correlations in Severe Methylenetetrahydrofolate Reductase Deficiency. *Am J Hum Genet* 56: 1052-9.
- van der Put NM, Gabreels F, Stevens EM, J A Smeitink, Trijbels FJ, et al. (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? *Am J Hum Genet* 62: 1044-51.
- Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, et al. (2000) Inherited Coagulation Disorders in Cirrhotic Patients With Portal Vein Thrombosis. *Hepatolo* 31: 345-8.
- Heller C, Schobess R, Kurnik K, Junker R, Günther G, et al. (2000) Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors: a multicentre case-control study. *Br J Haematol* 111: 534-9.
- Li XM, Wei YF, Hao HL, Hao YB, He LS, et al. (2002) Hyperhomocysteinemia and the MTHFR C677T mutation in Budd-Chiari syndrome. *Am J hematol* 71: 11-4.
- Pinto RB, Silveira TR, Bandinelli E, Röhsig L (2004) Portal vein thrombosis in children and adolescents: The low prevalence of hereditary thrombophilic disorders. *J Pediatr Surg* 39: 1356-61.
- Saxena R, Gupta PK, Ahmed RPH, Kannan M, Makharia G, et al. (2004) Inherited Prothrombotic Defects in Budd-Chiari Syndrome and Portal Vein Thrombosis : A Study From North India. *Am J clinic pathol* 121: 844-7.
- Erkan O, Bozdayi AM, Disibeyaz S, Oguz D, Ozcan M, et al. (2005) Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. *Eur J Gastroenterol & Hematopatol* 17: 339-43.
- Mangia A, Villani MR, Cappucci G, Santoro R, Ricciardi R, et al. (2005) Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. *Eur J Gastroenterol & Hematopatol* 17: 745-51.
- Pasta L, Marrone C, Amico DM, Virdone R, amico DG, et al. (2006) MTHFR C677T mutations in liver cirrhosis with and without portal vein thrombosis. *Liver international : official J Intern Assoc for the Study of the Liver* 26: 269-70.
- D'Amico M, Pasta L, Sammarco P (2009) MTHFR C677TT, PAII 4G-4G, V Leiden Q506, and prothrombin G20210A in hepatocellular carcinoma with and without portal vein thrombosis. *J thromb and thrombolysis* 28: 70-3.
- Gabr MA, Bessa SS, El-Zamarani EA (2010) Portal vein thrombosis in Egyptian patients with liver cirrhosis: Role of methylenetetrahydrofolate reductase C677T gene mutation. *Hepatology research : the official JI Japan Socief Hepatolo* 40: 486-93.
- Vaya A, Plume G, Bonet E, Carrasco P, Morales-Suarez-Varela MM (2011) Hyperhomocysteinemia and the methylene tetrahydrofolate reductase C677T mutation in splanchnic vein thrombosis. *Eur J Haematolo* 86: 167-72.
- Hu X-h (2008) Effect of plasma homocysteine, folic acid and polymorphisms in methylenetetrahydrofolate reductase on acute mesenteric vein thrombosis. *J China Medical uni* 37: 781-3.
- He JA, Hu XH, Fan YY (2010) Hyperhomocysteinemia, low folate concentrations and methylene tetrahydrofolate reductase C677T mutation in acute mesenteric venous thrombosis. *Eur J Vasc Endovasc Surg* 39: 508-13.
- Agaoglu N, Turkyilmaz S, Ovali E, Ucar F, Agaoglu C (2005) Prevalence of prothrombotic abnormalities in patients with acute mesenteric ischemia. *World J Surg* 29: 1135-8.
- Pinto R, Silveira T, Rosling L, Bandinelli E (2003) Thrombophilic disorders in children and adolescents with portal vein thrombosis. *J Pediatr* 79: 165-72.
- Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, et al. (2001) High Prevalence of Thrombophilic Genotypes in Patients With Acute Mesenteric Vein Thrombosis. *The Am J Gastroenterol* 96: 146-9.
- Amitrano L, Guardascione MA, Ames PR, Margaglione M, Antinolfi I, et al. (2003) Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. *Am J Hematol* 72: 75-81.
- Hoekstra J, Plessier A, García-Pagán J, F. Fabris, S. Darwish Murad, et al. (2010) Etiologic factors underlying Budd-Chiari syndrome and Portal Vein Thrombosis: clues for site-specific thrombosis. *Etiology and Clinical Outcome of Budd-Chiari Syndrome and Portal Vein Thrombosis*: 35.
- Barada KA, Aza CR, Otrrock ZK, Taher AT (2005) Budd-Chiari syndrome with underlying homozygous factor V Leiden and heterozygous methylenetetrahydrofolate reductase mutations. *J Gastroenterol* 40: 1002-3.
- Shamseddine A, Otrrock Z, Mahfouz R, Makarem J, Taher A (2005) Budd-Chiari syndrome in a paroxysmal nocturnal hemoglobinuria patient with coexistence of factor II and MTHFR mutations. *J Thrombosis and Haemostasis* 3: 1111.
- Sakr M, Barakat E, Abdelhakam S, Dabbous H, Yousuf S, et al. (2011) Epidemiological aspects of Budd-Chiari in Egyptian patients: a single-center study. *World J Gastroenterol* 17: 4704-10.
- Agaoglu N, Turkyilmaz S (2003) Prothrombotic Disorders in Patients With Mesenteric Vein Thrombosis. *J Invest Surg* 16: 299-304.
- Ricart JM, Vayá A, Todolí J, Calvo J, Villa P, et al. (2006) Thrombophilic risk factors and homocysteine levels in Behçet's disease in eastern Spain and their association with thrombotic events. *Thromb haemost* 95: 618-24.

32. Brattstrom L, Wilcken DEL, Ohrvik J, Brudin L (1998) Common Methylenetetrahydrofolate Reductase Gene Mutation Leads to Hyperhomocysteinemia but Not to Vascular Disease The Result of a Meta-Analysis. *Circulation* 98: 2520-6.
33. Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, et al. (2004) Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. *J Hepatol* 40: 736-41.
34. Colak Y, Karasu Z, Oruc N, Can C, Balým Z, et al. (2006) Hyperhomocysteinemia and factor V Leiden mutation are associated with Budd-Chiari syndrome. *Eur J Gastroenterol Hepatol* 18: 917-20.
35. Barada KA, Aza CR, Otrocko ZK, Taher AT (2005) Budd-Chiari syndrome with underlying homozygous factor V Leiden and heterozygous methylenetetrahydrofolate reductase mutations. *J Gastroenterol* 40: 1002-3.
36. Sakr M, Barakat E, Abdelhakam S, Abdelhakam S, Dabbous H, Yousuf S, et al. (2011) Epidemiological aspects of Budd-Chiari in Egyptian patients: a single-center study. *World J Gastroenterol* 17: 4704-10.
37. Ağaoglu N, Türkyılmaz S, Mustafa NA (2003) Prothrombotic Disorders in Patients With Mesenteric Vein Thrombosis. *J Investigat Surg* 16: 299-304.
38. Ricart JM, Vayá A, Todolí J, Calvo J, Villa P, et al. (2006) Thrombophilic risk factors and homocysteine levels in Behçet's disease in eastern Spain and their association with thrombotic events. *Thromb Haemost* 95: 618-24.
39. Brattstrom L, Wilcken DEL, Ohrvik J, Brudin L (1998) Common Methylenetetrahydrofolate Reductase Gene Mutation Leads to Hyperhomocysteinemia but Not to Vascular Disease The Result of a Meta-Analysis. *Circulation* 98: 2520-6.
40. Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, et al. (2004) Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. *J Hepatology* 40: 736-41.
41. Colak Y, Karasu Z, Oruc N, Can C, Balým Z, et al. (2006) Hyperhomocysteinemia and factor V Leiden mutation are associated with Budd-Chiari syndrome. *Eur J Gastroenterol Hepatol* 18: 917-20.
42. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. (1998) Hyperhomocysteinemia and Venous Thrombosis :A Meta-analysis. *Thromb Haemost* 80: 874-7.
43. Vučković BA, Čabarkapa VS, Ilić TA, Salatić IR, Lozanov-Crvenković ZS, et al. (2013) Clinical significance of determining plasma homocysteine: case-control study on arterial and venous thrombotic patients. *Croat Med J* 54: 480-8.
44. Frosst P, Blom HJ, ilos RM, Goyette P, Sheppard CA, et al. (1995) A candidate genetic risk factor for vascular disease:A common mutation in methylenetetrahydrofolate reductase. *Nat genet* 10: 111-3.
45. Heljer MD, Lewington S, Clarke R (2005) Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. *J Thromb Haemost* 3: 292-9.
46. Kenet G, Lutkhoff LK, Albisetti M, Bernard T, Bonduel M et al. (2010) Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. *Circulation* 121: 1838-47.
47. Eldorriy A, Barakat E, Abdella H, Abdelhakam S, Shaker M, et al. (2011) Outcome of non surgical hepatic decompression procedures in Egyptian patients with Budd-Chiari. *World J gastroenterol* 17: 906-13.
48. Qi X, Wu F, Ren W, He C, Yin Z, et al. (2013) Thrombotic risk factors in Chinese Budd-Chiari syndrome patients. An observational study with a systematic review of the literature. *Thromb Haemost* 109: 878-84.

Submit your next manuscript to Annex Publishers and benefit from:

- ▶ Easy online submission process
- ▶ Rapid peer review process
- ▶ Online article availability soon after acceptance for Publication
- ▶ Open access: articles available free online
- ▶ More accessibility of the articles to the readers/researchers within the field
- ▶ Better discount on subsequent article submission

Submit your manuscript at

<http://www.annexpublishers.com/paper-submission.php>